NYSE:JNJPharmaceuticals
Johnson & Johnson Taps Royalty Pharma To Support Immunology Growth Plans
Johnson & Johnson (NYSE:JNJ) has entered a US$500 million R&D co-funding agreement with Royalty Pharma.
The partnership is focused on advancing JNJ-4804, a first in class co-antibody therapy targeting IL-23 and TNF pathways.
The therapy is being developed for chronic immune mediated diseases within J&J's immunology franchise.
For investors watching NYSE:JNJ, this move highlights how central immunology remains to the company’s long term plan. J&J already has an active presence in immune...